 |
市場調查報告書
商品編碼
2033994
全球醫藥合約研究組織（CRO）服務市場：按類型、交付模式、方式、治療領域、最終用戶和地區分類－預測至2031年Contract Research Organization (CRO) Services Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area, Modality, Model (FSO, FSP), End User, Competition - Global Forecast to 2031 |
||||||
價格
預計在預測期內，醫藥研發合約組織 (CRO) 服務的市場規模將以 8.6% 的複合年成長率成長，從 2026 年的 930.2 億美元成長到 2031 年的 1403.2 億美元。
推動市場成長的關鍵因素包括細胞和基因治療產品線的擴張以及對精準醫療日益成長的關注。這些因素預計將促使申辦公司尋求能夠處理複雜試驗設計、基因組篩檢、客製化物流以及內部難以實施的必要長期追蹤能力的合約研究組織 (CRO) 合作夥伴。
| 調查範圍 | |
|---|---|
| 調查期 | 2026-2031 |
| 基準年 | 2025 |
| 預測期 | 2026-2031 |
| 目標單元 | 金額（10億美元） |
| 部分 | 按類型、交付模式、治療方式、治療區域、最終用戶、地區 |
| 目標區域 | 北美、歐洲、亞太地區、拉丁美洲、中東和非洲 |
精準醫療計畫透過細分病患群體並縮短入組時間，使得整合的CRO-實驗室網路和全球試驗中心成為研發進度和資料品質的關鍵因素。隨著監管機構和保險公司對可靠、即時證據的需求日益成長，申辦方越來越依賴那些能夠提供具備先進實驗室、資料科學和真實世界數據（RWE）能力的臨床服務的CRO，以降低研發風險。
從服務類型來看，預計到 2025 年，早期開發服務領域將佔據 CRO 服務市場第二大佔有率。
按服務類型分類，CRO服務市場可細分為臨床研究、早期開發、測試、諮詢和資料管理服務。預計到2025年，早期開發服務將佔據第二大市場。目前的研發管線主要集中在新型生技藥品、細胞基因療法和標靶治療的開發上，這些都需要專業的毒理學、藥物代謝動力學、生物分析和安全性藥理學研究。許多申辦者傾向於將這些工作外包，以加速其進入IND（臨床實驗藥物）階段的進程。
就最終用戶而言，到 2025 年，製藥和生物製藥公司將在 CRO 服務市場中佔據最大佔有率。
從終端用戶角度來看，CRO服務市場可細分為製藥和生物製藥公司、醫療設備公司以及學術機構。預計到2025年，製藥和生物製藥公司將佔據CRO服務市場最大的佔有率。這一龐大的終端用戶佔有率主要歸功於製藥和生技公司眾多在研發線產品。此外，CRO以其速度、規模優勢和靈活的成本結構吸引終端用戶。
按地區分類，北美在 2025 年佔據最大的市場佔有率。
到2025年，北美將佔據全球CRO服務市場最大的佔有率。這主要得益於該地區成熟的製藥和生技產業，這些產業對外包研發服務有著龐大的需求。此外，遍布各地的臨床試驗中心、醫院和專業設施為在該地區進行大規模臨床試驗提供了理想的基礎設施。同時，美國對數位醫療解決方案和分散式試驗模式的快速應用，也進一步推動了該地區市場佔有率的成長，因為申辦方正在尋求創新方法來提高患者招募和留存率，從而進一步刺激了對CRO的需求。
本報告涵蓋的公司簡介清單：
- IQVIA Inc.（美國）、ICON plc（愛爾蘭）、賽默飛世爾科技公司（美國）、美國實驗室控股公司（LabCorp）（美國）、Fortrea, Inc.（美國）、Syneos Health（美國）、藥明康德（中國）、查爾斯河實驗室（美國）、PAREXEL International Corporation（美國）、Pharmaron（中國）、SGS）、SGSs（AGS）、SGSs SApace） Scientific（盧森堡）、BioAgile（印度）、Firma Clinical Research（美國）、Acculab Life Sciences（美國）、Novotech（澳洲）、KCR SA（美國）、Clinical（日本）、Advanced Clinical（美國）
- Allucent（美國）、臨床試驗服務公司（荷蘭）、Guires Inc.（Pepgra Healthcare Pvt. Ltd.）（英國）、Worldwide Clinical Trials（美國）、CTI Clinical Trial And Consulting（美國）
調查範圍
本研究報告按類型、方式、交付模式、最終用戶和地區對CRO服務市場進行細分。報告詳細闡述了影響CRO服務市場成長的關鍵因素，包括促進因素、阻礙因素、挑戰和機會。對主要產業參與者的深入分析，揭示了他們的業務概況、服務、關鍵策略、夥伴關係和協議。新產品發布、夥伴關係和收購是CRO服務市場近期發展的重要動態。
購買本報告的主要好處
本報告透過提供整個CRO服務市場及其細分市場最準確的收入預測，幫助市場領導和新參與企業。它還有助於相關人員更深入了解競爭格局，更有效地進行業務定位，並制定合適的打入市場策略。本報告使相關人員能夠掌握市場趨勢，並獲取有關關鍵市場促進因素、機會和挑戰的資訊。
本報告深入分析了以下幾點：
- 分析影響市場成長的關鍵促進因素（越來越重視分散式臨床試驗、臨床試驗的複雜性和數量不斷增加以及 CRO 提供的服務的柔軟性）、機會（監管機構對患者多樣性的關注）和挑戰（患者留存挑戰、網路安全和智慧財產權問題）。
- 服務開發/創新：深入洞察CRO服務市場的新服務
- 市場發展：盈利市場的全面資訊－本報告分析了各個地區的市場。
- 市場多元化：有關 CRO 服務市場的新服務、未開發的地區、最新趨勢和投資的全面資訊。
- 競爭格局分析：對主要參與者的市場佔有率、成長策略和服務產品進行詳細評估，這些參與者包括IQVIA Inc.（美國）、ICON Plc（愛爾蘭）、Medpace（美國）、Laboratory Corporation of America Holdings (LabCorp)（美國）、Thermo Fisher Scientific Inc.（美國）和Fortrea, Inc.（美國）。這項對主要產業參與者的深入分析，揭示了他們在CRO服務市場中的關鍵策略、服務推出、收購、合作、協議、合資企業、業務擴張、其他近期發展、投資和資金籌措活動、品牌/服務對比分析、供應商評估以及財務指標。
目錄
第1章：引言
第2章執行摘要
第3章重要考察
第4章 市場概覽
- 市場動態
- 促進因素
- 機會
- 任務
- 未滿足的需求和未開發的領域
- 相互關聯的市場與跨產業機遇
- 一級/二級/三級公司的策略性舉措
第5章 產業趨勢
- 市場趨勢
- 波特五力分析
- 宏觀經濟展望
- 價值鏈分析
- 生態系分析
- 價格分析
- 2026-2027 年主要會議和活動
- 影響我們客戶公司業務的趨勢/變化
- 投資和資金籌措場景
- 2025年美國關稅對CRO服務市場的影響
第6章：科技進步、人工智慧的影響、創新與未來應用
- 主要技術
- 互補技術
- 鄰近技術
- 技術/服務藍圖
- 未來應用
- 人工智慧/通用人工智慧對CRO服務市場的影響
第7章：監理情勢與永續性舉措
- 當地法規和合規性
- 監管機構、政府機構和其他組織
- 業界標準
- 認證、標籤檢視和環境標準
- 監管分析
- 藥品核准和現行藥品生產品質管理規範（CGMP）程序的監管情景
- 對永續性的承諾
第8章：顧客趨勢與購買行為
- 決策流程
- 採購過程中的關鍵相關人員及其評估標準
- 客戶狀況
- 各個終端用戶產業尚未滿足的需求
- 市場盈利
第9章：CRO服務市場（按類型分類）
- 臨床研究服務
- 早期發展階段的服務
- 檢查服務
- 諮詢服務
- 資料管理服務
第10章：CRO 服務市場（依交付模式分類）
- 全方位服務外包（FSO）模式
- 功能服務供應商（FSP）模型
- 混合模式
第11章：CRO 服務市場（依治療方式分類）
- 低分子
- 生物製藥
- 醫療設備
- 生物相似藥
第12章：CRO服務市場（依治療領域分類）
- 腫瘤學
- 感染疾病
- 心血管疾病
- 神經病學
- 疫苗
- 代謝性疾病/內分泌學
- 免疫疾病
- 精神病學
- 呼吸系統疾病
- 皮膚科
- 眼科
- 消化系統疾病
- 泌尿生殖系統與女性健康
- 血液學
- 其他
第13章：CRO 服務市場（依最終用戶分類）
- 製藥和生物製藥公司
- 醫療設備公司
- 學術機構
第14章：CRO服務市場（依地區分類）
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 其他
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- 其他
- 拉丁美洲
- 巴西
- 墨西哥
- 其他
- 中東
- 海灣合作理事會國家
- 其他
- 非洲
- 蓬勃發展的製藥業是推動成長的主要動力。
第15章 競爭格局
- 主要參與企業的策略/優勢
- 2021-2025年收入分析
- 2025年市佔率分析
- 企業估值矩陣：主要公司，2025 年
- 公司估值矩陣：新創企業/中小企業，2025 年
- 企業估值和財務指標
- 服務比較
- 競爭格局
第16章：公司簡介
- 主要參與企業
- IQVIA INC.
- ICON PLC
- THERMO FISHER SCIENTIFIC INC.
- LABORATORY CORPORATION OF AMERICA HOLDINGS
- FORTREA, INC.
- SYNEOS HEALTH
- WUXI APPTEC
- CHARLES RIVER LABORATORIES
- PAREXEL INTERNATIONAL CORPORATION
- PHARMARON
- MEDPACE
- SGS SA
- FRONTAGE LABS
- EUROFINS SCIENTIFIC
- TIGERMED
- PSI CRO AG
- BIOAGILE
- FIRMA CLINICAL RESEARCH
- ACCULAB LIFE SCIENCES
- NOVOTECH
- LINICAL
- ADVANCED CLINICAL
- 其他公司
- ALLUCENT
- EMVENIO
- GUIRES INC.（PEPGRA HEALTHCARE PVT. LTD.）
- WORLDWIDE CLINICAL TRIALS
- CTI CLINICAL TRIAL & CONSULTING
第17章調查方法
第18章附錄
Product Code: PH 4672
The contract research organization (CRO) services market is expected to reach USD 140.32 billion in 2031 from USD 93.02 billion in 2026, at a CAGR of 8.6% during the forecast period. The key factors contributing to market growth include the expanding pipeline of cell & gene therapies and the growing focus on precision medicine. These factors are expected to drive sponsors toward CRO partners that can handle complex designs, genomic screening, customizable logistics, and mandatory long-term follow-up capabilities that are challenging to implement in-house.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Type, Modality, Therapeutic Area, Delivery Model, and End User |
| Regions covered | North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa |
Precision programs fragment patient cohorts and shorten enrollment windows, making integrated CRO-lab networks and global site coverage decisive for timelines and data quality. As regulators and payers demand robust, real-time evidence, sponsors increasingly depend on CROs that offer clinical operations with advanced lab, data science, and RWE capabilities to de-risk development.
By service type, the early phase development services segment accounted for the second-largest share of the CRO services market in 2025.
Based on service type, the CRO services market is segmented into clinical research, early-phase development, laboratory, consulting, and data management services. In 2025, the early phase development services segment accounted for the second-largest share of the market. The current pipeline is focused on developing novel biologics, CGT, and targeted modalities that require specialized toxicology, DMPK, bioanalysis, and safety pharmacology, which several sponsors prefer to outsource to reach the IND (investigational new drug) stage faster.
By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the CRO services market in 2025.
Based on end user, the CRO services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. In 2025, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the CRO services market. The large share of this end-user segment can be attributed to the large number of drug pipeline products of pharma and biotech companies. Moreover, CROs deliver speed, scale, and flexible cost bases, attracting end users.
By region, North America accounted for the largest share of the market in 2025.
In 2025, North America held the largest share of the global CRO services market, driven by the presence of well-established pharmaceutical and biotechnology industries, which drive significant demand for outsourced research and development services. Additionally, a vast network of clinical sites, hospitals, and specialized facilities provides an ideal infrastructure for conducting large-scale clinical trials in the region. Additionally, the rapid adoption of digital health solutions and decentralized trial models in the US, a significant contributor to the region's substantial share, is further boosting CRO demand, as sponsors seek innovative ways to improve patient recruitment and retention.
List of Companies Profiled in the Report:
- IQVIA Inc. (US)
- ICON plc (Ireland)
- Thermo Fisher Scientific Inc. (US)
- Laboratory Corporation of America Holdings (LabCorp) (US)
- Fortrea, Inc. (US)
- Syneos Health (US)
- WuXi AppTec (China)
- Charles River Laboratories (US)
- PAREXEL International Corporation (US)
- Pharmaron (China)
- Medpace (US)
- SGS SA (Switzerland), Frontage Labs (US)
- Eurofins Scientific (Luxembourg)
- BioAgile (India)
- Firma Clinical Research (US)
- Acculab Life Sciences (US)
- Novotech (Australia)
- KCR S.A. (US)
- Linical (Japan)
- Advanced Clinical (US)
- Allucent (US)
- Clinical Trial Service (Netherlands)
- Guires Inc. (Pepgra Healthcare Pvt. Ltd.) (UK)
- Worldwide Clinical Trials (US)
- CTI Clinical Trial And Consulting (US)
Research Coverage
This research report categorizes the CRO services market by type (clinical research services, early-phase development services, laboratory services, consulting services, and data management services), modality (small molecules, biologics, biosimilars, medical devices), delivery model (Full-service outsourcing (FSO) model, Functional service provider (FSP) model, Hybrid model), end user (pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRO services market. A thorough analysis of the key industry players has provided insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, partnerships, and acquisitions are the recent developments associated with the CRO services market.
Key Benefits of Buying the Report
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall CRO services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, opportunities, and challenges.
The report provides insights into the following pointers:
- Analysis of key drivers (increasing focus on decentralized trials, rising complexity and volume of trials, service flexibility offered by CROs), opportunities (regulatory focus on patient pool diversity), and challenges (challenges of patient retention and cybersecurity/intellectual property concerns) influencing the growth of the market.
- Service Development/Innovation: Detailed insights on newly launched services of the CRO services market
- Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the CRO services market
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of key players, including IQVIA Inc. (US), ICON Plc (Ireland), Medpace (US), Laboratory Corporation of America Holdings (LabCorp) (US), Thermo Fisher Scientific Inc. (US), and Fortrea, Inc. (US). A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, service launches, acquisitions, partnerships, agreements, collaborations, expansions, other recent developments, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics of the CRO services market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 GLOBAL CRO SERVICES MARKET SNAPSHOT
- 3.2 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY AND COUNTRY, 2024
- 3.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Rising trial volume and complexity
- 4.2.1.2 Growing focus on decentralized/patient-centric trials
- 4.2.1.3 Service flexibility offered by CROs
- 4.2.1.4 Technological integrations
- 4.2.1.5 Growing R&D investments and presence of a robust clinical pipeline
- 4.2.2 OPPORTUNITIES
- 4.2.2.1 Growing regulatory stringency on the diversity of the patient pool
- 4.2.2.2 Risk-based monitoring (RBM) and risk-based quality management as a service
- 4.2.2.3 Offering data analysis outcomes favoring clients' reimbursement and market access strategy
- 4.2.2.4 AI-powered clinical development and decentralized trial models
- 4.2.3 CHALLENGES
- 4.2.3.1 Patient retention
- 4.2.3.2 Cybersecurity or intellectual property challenges
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 MARKET TRENDS
- 5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN
- 5.1.2 IN SILICO TRIALS
- 5.1.3 SPECIALIZED BIOANALYTICS FOR EMERGING MODALITIES (CGT)
- 5.2 PORTER'S FIVE FORCES ANALYSIS
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 THREAT OF SUBSTITUTES
- 5.2.3 BARGAINING POWER OF BUYERS
- 5.2.4 BARGAINING POWER OF SUPPLIERS
- 5.2.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.3 MACROECONOMIC OUTLOOK
- 5.3.1 INTRODUCTION
- 5.3.2 GDP TRENDS AND FORECAST
- 5.3.3 TRENDS IN GLOBAL CRO SERVICES MARKET
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 PRICING ANALYSIS
- 5.6.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025
- 5.6.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025
- 5.6.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
- 5.7 KEY CONFERENCES & EVENTS, 2026-2027
- 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.9 INVESTMENT AND FUNDING SCENARIO
- 5.10 IMPACT OF 2025 US TARIFFS-CRO SERVICES MARKET
- 5.10.1 INTRODUCTION
- 5.10.2 KEY TARIFF RATES
- 5.10.3 PRICE IMPACT ANALYSIS
- 5.10.4 IMPACT ON COUNTRIES/REGIONS
- 5.10.4.1 North America
- 5.10.4.1.1 US
- 5.10.4.2 Europe
- 5.10.4.3 Asia Pacific
- 5.10.4.1 North America
- 5.10.5 IMPACT ON END-USE INDUSTRIES
- 5.10.5.1 Pharmaceutical & biotech companies
- 5.10.5.2 Medical device companies
- 5.10.5.3 Academic institutes
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY TECHNOLOGIES
- 6.1.1 AI-INTEGRATED CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) & ELECTRONIC TRIAL MASTER FILE (ETMF) PLATFORMS
- 6.1.2 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM)
- 6.1.3 ELECTRONIC DATA CAPTURE (EDC) SYSTEM
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 DIGITAL BIOMARKERS, WEARABLES & ELECTRONIC PATIENT-REPORTED OUTCOME (EPRO) TOOLS
- 6.2.2 MODEL-INFORMED DRUG DEVELOPMENT (MIDD)
- 6.2.3 DATA MANAGEMENT AND INFORMATICS TECHNOLOGIES
- 6.2.4 REAL-WORLD EVIDENCE (RWE) & REAL-WORLD DATA (RWD) PLATFORMS
- 6.3 ADJACENT TECHNOLOGIES
- 6.3.1 CLINICAL TRIAL SIMULATION TOOLS
- 6.4 TECHNOLOGY/SERVICE ROADMAP
- 6.5 FUTURE APPLICATIONS
- 6.6 IMPACT OF AI/GEN AI ON CRO SERVICES MARKET
- 6.6.1 INTRODUCTION
- 6.6.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES
- 6.6.3 AI USE CASES
- 6.6.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Rest of the World
- 7.1.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS
- 7.1.4 REGULATORY ANALYSIS
- 7.1.5 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
- 7.2 SUSTAINABILITY INITIATIVES
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 BUYING CRITERIA
- 8.3 CUSTOMER LANDSCAPE
- 8.3.1 BUDGET ALLOCATION TREND
- 8.3.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
9 CRO SERVICES MARKET, BY TYPE
- 9.1 INTRODUCTION
- 9.2 CLINICAL RESEARCH SERVICES
- 9.2.1 PHASE III
- 9.2.1.1 Large-scale testing ability to assess efficacy and safety of drugs to aid growth
- 9.2.2 PHASE II
- 9.2.2.1 Growing number of pipeline products in Phase II studies to drive market
- 9.2.3 PHASE I
- 9.2.3.1 Robust pipeline of pharmaceutical and biopharmaceutical products to support growth
- 9.2.4 PHASE IV
- 9.2.4.1 Stringent global regulations for drug safety monitoring to spur growth
- 9.2.1 PHASE III
- 9.3 EARLY-PHASE DEVELOPMENT SERVICES
- 9.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES
- 9.3.1.1 Growing need to meet regulatory norms for drugs to fuel market
- 9.3.2 PRECLINICAL SERVICES
- 9.3.2.1 Pharmacokinetics/Pharmacodynamics
- 9.3.2.1.1 Rise in outsourcing services by pharmaceutical and biopharmaceutical companies to promote growth
- 9.3.2.2 Toxicology testing
- 9.3.2.2.1 Need to prevent late-stage failures to contribute to growth
- 9.3.2.3 Other preclinical services
- 9.3.2.1 Pharmacokinetics/Pharmacodynamics
- 9.3.3 DISCOVERY STUDIES
- 9.3.3.1 Increasing reliance on CRO services for target identification and validation to expedite growth
- 9.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES
- 9.4 LABORATORY SERVICES
- 9.4.1 ANALYTICAL TESTING
- 9.4.1.1 Physical characterization
- 9.4.1.1.1 Ability to minimize product failure in late-phase development to favor growth
- 9.4.1.2 Raw material testing
- 9.4.1.2.1 Need to maintain quality of finished product to facilitate growth
- 9.4.1.3 Batch-release testing
- 9.4.1.3.1 Need to maintain batch-to-batch consistency of pharmaceutical dosage forms to advance growth
- 9.4.1.4 Stability testing
- 9.4.1.4.1 Ability to establish drug compatibility and formulation development to aid growth
- 9.4.1.5 Other analytical testing services
- 9.4.1.1 Physical characterization
- 9.4.2 BIOANALYTICAL TESTING
- 9.4.2.1 Increasing outsourcing of R&D activities to accelerate growth
- 9.4.1 ANALYTICAL TESTING
- 9.5 CONSULTING SERVICES
- 9.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO BOOST MARKET
- 9.6 DATA MANAGEMENT SERVICES
- 9.6.1 NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH
10 CRO SERVICES MARKET, BY DELIVERY MODEL
- 10.1 INTRODUCTION
- 10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL
- 10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
- 10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
- 10.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
- 10.4 HYBRID MODEL
- 10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH
11 CRO SERVICES MARKET, BY MODALITY
- 11.1 INTRODUCTION
- 11.2 SMALL MOLECULES
- 11.2.1 ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH
- 11.3 BIOLOGICS
- 11.3.1 MONOCLONAL ANTIBODIES
- 11.3.1.1 Surging demand for targeted therapies across oncology, autoimmune disorders, and infectious diseases to drive market
- 11.3.2 CELL & GENE THERAPY
- 11.3.2.1 Robust pipeline and R&D initiatives to drive market
- 11.3.3 OTHER BIOLOGICS
- 11.3.1 MONOCLONAL ANTIBODIES
- 11.4 MEDICAL DEVICES
- 11.4.1 RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLES, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH
- 11.5 BIOSIMILARS
- 11.5.1 MONOCLONAL ANTIBODY BIOSIMILARS
- 11.5.1.1 Rising demand for affordable therapeutic options to support growth
- 11.5.2 INSULIN
- 11.5.2.1 Increasing patent expirations to contribute to growth
- 11.5.3 COLONY-STIMULATING FACTORS
- 11.5.3.1 Increasing use of colony-stimulating factor during post-chemotherapy to aid growth
- 11.5.4 ERYTHROPOIETIN
- 11.5.4.1 Essential role of erythropoietin in treating anemia to stimulate growth
- 11.5.5 OTHER BIOSIMILARS
- 11.5.1 MONOCLONAL ANTIBODY BIOSIMILARS
12 CRO SERVICES MARKET, BY THERAPEUTIC AREA
- 12.1 INTRODUCTION
- 12.2 ONCOLOGY
- 12.2.1 GROWING INCIDENCE OF CANCER TO DRIVE MARKET
- 12.2.2 BREAST CANCER
- 12.2.2.1 Increasing cases and high spending on treating breast cancer to support growth
- 12.2.3 LUNG CANCER
- 12.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth
- 12.2.4 COLORECTAL CANCER
- 12.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth
- 12.2.5 PROSTATE CANCER
- 12.2.5.1 Growing clinical pipeline to propel market
- 12.2.6 OTHER CANCERS
- 12.3 INFECTIOUS DISEASES
- 12.3.1 INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH
- 12.4 CARDIOVASCULAR SYSTEM DISORDERS
- 12.4.1 HIGH MORTALITY RATES OF CARDIOVASCULAR DISEASES TO FUEL MARKET
- 12.5 NEUROLOGY
- 12.5.1 GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET
- 12.6 VACCINES
- 12.6.1 INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH
- 12.7 METABOLIC DISORDERS/ENDOCRINOLOGY
- 12.7.1 INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH
- 12.8 IMMUNOLOGICAL DISORDERS
- 12.8.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
- 12.9 PSYCHIATRY
- 12.9.1 RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH
- 12.10 RESPIRATORY DISORDERS
- 12.10.1 RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH
- 12.11 DERMATOLOGY
- 12.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET
- 12.12 OPHTHALMOLOGY
- 12.12.1 GROWTH IN NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
- 12.13 GASTROINTESTINAL DISEASES
- 12.13.1 RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH
- 12.14 GENITOURINARY & WOMEN'S HEALTH
- 12.14.1 RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER MARKET
- 12.15 HEMATOLOGY
- 12.15.1 INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH
- 12.16 OTHER THERAPEUTIC AREAS
13 CRO SERVICES MARKET, BY END USER
- 13.1 INTRODUCTION
- 13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 13.2.1 INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH
- 13.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 13.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs
- 13.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
- 13.2.3.1 Demand is driven by need to control fixed costs, access global development expertise, and accelerate timelines
- 13.3 MEDICAL DEVICE COMPANIES
- 13.3.1 INCREASING GROWTH INITIATIVES BY MEDTECH CROS TO DRIVE MARKET
- 13.4 ACADEMIC INSTITUTES
- 13.4.1 CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH
14 CRO SERVICES MARKET, BY REGION
- 14.1 INTRODUCTION
- 14.2 NORTH AMERICA
- 14.2.1 US
- 14.2.1.1 Increasing incidence of oncology indications to accelerate growth
- 14.2.2 CANADA
- 14.2.2.1 Favorable government initiatives and high investments to support growth
- 14.2.1 US
- 14.3 EUROPE
- 14.3.1 GERMANY
- 14.3.1.1 Presence of strong pharmaceutical and biotechnology R&D infrastructure to spur growth
- 14.3.2 UK
- 14.3.2.1 Rising pharmaceutical R&D expenditure to expedite growth
- 14.3.3 FRANCE
- 14.3.3.1 Increasing technological advancements and faster drug discovery and development initiatives to aid growth
- 14.3.4 ITALY
- 14.3.4.1 Short timeline for drug approvals to encourage growth
- 14.3.5 SPAIN
- 14.3.5.1 Growing investment in pharmaceutical industry to boost market
- 14.3.6 REST OF EUROPE
- 14.3.1 GERMANY
- 14.4 ASIA PACIFIC
- 14.4.1 CHINA
- 14.4.1.1 Continued efforts on improving the level of drug safety and supply to spur growth
- 14.4.2 INDIA
- 14.4.2.1 Large pool of patients and presence of highly skilled medical professionals to augment growth
- 14.4.3 JAPAN
- 14.4.3.1 Growing drug development activity to propel market
- 14.4.4 AUSTRALIA
- 14.4.4.1 Growing focus on funding opportunities to propel market
- 14.4.5 SOUTH KOREA
- 14.4.5.1 Emerging clinical research hub to sustain growth
- 14.4.6 REST OF ASIA PACIFIC
- 14.4.1 CHINA
- 14.5 LATIN AMERICA
- 14.5.1 BRAZIL
- 14.5.1.1 Growing focus on enhancing pharmaceutical research and production to fuel market
- 14.5.2 MEXICO
- 14.5.2.1 Increasing investments in pharma R&D to promote growth
- 14.5.3 REST OF LATIN AMERICA
- 14.5.1 BRAZIL
- 14.6 MIDDLE EAST
- 14.6.1 GCC COUNTRIES
- 14.6.1.1 Kingdom of Saudi Arabia (KSA)
- 14.6.1.1.1 Expanding clinical trials ecosystem to contribute to growth
- 14.6.1.2 United Arab Emirates (UAE)
- 14.6.1.2.1 Growing clinical trials activity to drive market
- 14.6.1.3 Rest of GCC Countries
- 14.6.1.1 Kingdom of Saudi Arabia (KSA)
- 14.6.2 REST OF MIDDLE EAST
- 14.6.1 GCC COUNTRIES
- 14.7 AFRICA
- 14.7.1 BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH
15 COMPETITIVE LANDSCAPE
- 15.1 INTRODUCTION
- 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026
- 15.3 REVENUE ANALYSIS, 2021-2025
- 15.4 MARKET SHARE ANALYSIS, 2025
- 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 15.5.1 STARS
- 15.5.2 EMERGING LEADERS
- 15.5.3 PERVASIVE PLAYERS
- 15.5.4 PARTICIPANTS
- 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 15.5.5.1 Company footprint
- 15.5.5.2 Region footprint
- 15.5.5.3 Type footprint
- 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 15.6.1 PROGRESSIVE COMPANIES
- 15.6.2 RESPONSIVE COMPANIES
- 15.6.3 DYNAMIC COMPANIES
- 15.6.4 STARTING BLOCKS
- 15.6.5 COMPETITIVE BENCHMARKING
- 15.6.5.1 Detailed list of key startups/SMEs
- 15.6.5.2 Competitive benchmarking of startups/SMEs
- 15.7 COMPANY VALUATION & FINANCIAL METRICS
- 15.7.1 FINANCIAL METRICS
- 15.7.2 COMPANY VALUATION
- 15.8 SERVICE COMPARISON
- 15.9 COMPETITIVE SCENARIO
- 15.9.1 SERVICE LAUNCHES & APPROVALS
- 15.9.2 DEALS
- 15.9.3 EXPANSIONS
16 COMPANY PROFILES
- 16.1 KEY PLAYERS
- 16.1.1 IQVIA INC.
- 16.1.1.1 Business overview
- 16.1.1.2 Services/Solutions offered
- 16.1.1.3 Recent developments
- 16.1.1.3.1 Product & service launches
- 16.1.1.3.2 Deals
- 16.1.1.4 MnM view
- 16.1.1.4.1 Key strengths/Right to win
- 16.1.1.4.2 Strategic choices made
- 16.1.1.4.3 Weaknesses and competitive threats
- 16.1.2 ICON PLC
- 16.1.2.1 Business overview
- 16.1.2.2 Services/Solutions offered
- 16.1.2.3 Recent developments
- 16.1.2.3.1 Service launches
- 16.1.2.3.2 Deals
- 16.1.2.3.3 Expansions
- 16.1.2.4 MnM view
- 16.1.2.4.1 Key strengths/Right to win
- 16.1.2.4.2 Strategic choices made
- 16.1.2.4.3 Weaknesses and competitive threats
- 16.1.3 THERMO FISHER SCIENTIFIC INC.
- 16.1.3.1 Business overview
- 16.1.3.2 Services/Solutions offered
- 16.1.3.3 Recent developments
- 16.1.3.3.1 Service launches
- 16.1.3.3.2 Deals
- 16.1.3.3.3 Expansions
- 16.1.3.4 MnM view
- 16.1.3.4.1 Key strengths/Right to win
- 16.1.3.4.2 Strategic choices made
- 16.1.3.4.3 Weaknesses and competitive threats
- 16.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
- 16.1.4.1 Business overview
- 16.1.4.2 Services/Solutions offered
- 16.1.4.3 Recent developments
- 16.1.4.3.1 Service launches
- 16.1.4.3.2 Deals
- 16.1.4.3.3 Expansions
- 16.1.4.3.4 Other developments
- 16.1.4.4 MnM view
- 16.1.4.4.1 Key strengths/Right to win
- 16.1.4.4.2 Strategic choices made
- 16.1.4.4.3 Weaknesses and competitive threats
- 16.1.5 FORTREA, INC.
- 16.1.5.1 Company overview
- 16.1.5.2 Services/Solutions offered
- 16.1.5.3 Recent developments
- 16.1.5.3.1 Service launches
- 16.1.5.3.2 Deals
- 16.1.5.3.3 Expansions
- 16.1.5.3.4 Other developments
- 16.1.5.4 MnM view
- 16.1.5.4.1 Key strengths/Right to win
- 16.1.5.4.2 Strategic choices made
- 16.1.5.4.3 Weaknesses and competitive threats
- 16.1.6 SYNEOS HEALTH
- 16.1.6.1 Business overview
- 16.1.6.2 Services/Solutions offered
- 16.1.6.3 Recent developments
- 16.1.6.3.1 Service launches
- 16.1.6.3.2 Deals
- 16.1.7 WUXI APPTEC
- 16.1.7.1 Business overview
- 16.1.7.2 Services/Solutions offered
- 16.1.7.3 Recent developments
- 16.1.7.3.1 Expansions
- 16.1.7.3.2 Other developments
- 16.1.8 CHARLES RIVER LABORATORIES
- 16.1.8.1 Business overview
- 16.1.8.2 Services/Solutions offered
- 16.1.8.3 Recent developments
- 16.1.8.3.1 Deals
- 16.1.9 PAREXEL INTERNATIONAL CORPORATION
- 16.1.9.1 Business overview
- 16.1.9.2 Services/Solutions offered
- 16.1.9.3 Recent developments
- 16.1.9.3.1 Deals
- 16.1.9.3.2 Expansions
- 16.1.10 PHARMARON
- 16.1.10.1 Business overview
- 16.1.10.2 Services/Solutions offered
- 16.1.11 MEDPACE
- 16.1.11.1 Business overview
- 16.1.11.2 Services/Solutions offered
- 16.1.12 SGS SA
- 16.1.12.1 Business overview
- 16.1.12.2 Services/Solutions offered
- 16.1.12.3 Recent developments
- 16.1.12.3.1 Deals
- 16.1.13 FRONTAGE LABS
- 16.1.13.1 Business overview
- 16.1.13.2 Services/Solutions offered
- 16.1.13.3 Recent developments
- 16.1.13.3.1 Deals
- 16.1.13.3.2 Other developments
- 16.1.14 EUROFINS SCIENTIFIC
- 16.1.14.1 Business overview
- 16.1.14.2 Services/Solutions offered
- 16.1.15 TIGERMED
- 16.1.15.1 Business overview
- 16.1.15.2 Services offered
- 16.1.15.3 Recent developments
- 16.1.15.3.1 Product/Service approvals
- 16.1.15.3.2 Deals
- 16.1.16 PSI CRO AG
- 16.1.16.1 Business overview
- 16.1.16.2 Services/Solutions offered
- 16.1.16.3 Recent developments
- 16.1.16.3.1 Service launches
- 16.1.16.3.2 Deals
- 16.1.16.3.3 Expansions
- 16.1.17 BIOAGILE
- 16.1.17.1 Business overview
- 16.1.17.2 Services/Solutions offered
- 16.1.18 FIRMA CLINICAL RESEARCH
- 16.1.18.1 Business overview
- 16.1.18.2 Services/Solutions offered
- 16.1.19 ACCULAB LIFE SCIENCES
- 16.1.19.1 Business overview
- 16.1.19.2 Services/Solutions offered
- 16.1.20 NOVOTECH
- 16.1.20.1 Business overview
- 16.1.20.2 Services/Solutions offered
- 16.1.20.3 Recent developments
- 16.1.20.3.1 Deals
- 16.1.21 LINICAL
- 16.1.21.1 Business overview
- 16.1.21.2 Services/Solutions offered
- 16.1.21.3 Recent developments
- 16.1.21.3.1 Expansions
- 16.1.22 ADVANCED CLINICAL
- 16.1.22.1 Business overview
- 16.1.22.2 Services/Solutions offered
- 16.1.22.3 Recent developments
- 16.1.22.3.1 Deals
- 16.1.1 IQVIA INC.
- 16.2 OTHER PLAYERS
- 16.2.1 ALLUCENT
- 16.2.2 EMVENIO
- 16.2.3 GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.)
- 16.2.4 WORLDWIDE CLINICAL TRIALS
- 16.2.5 CTI CLINICAL TRIAL & CONSULTING
17 RESEARCH METHODOLOGY
- 17.1 RESEARCH APPROACH
- 17.1.1 SECONDARY DATA
- 17.1.1.1 Key sources of secondary data
- 17.1.1.2 Key objectives of secondary research
- 17.1.2 PRIMARY DATA
- 17.1.2.1 Breakdown of primaries
- 17.1.2.2 Key objectives of primary research
- 17.1.1 SECONDARY DATA
- 17.2 MARKET ESTIMATION METHODOLOGY
- 17.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
- 17.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH
- 17.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
- 17.3 GROWTH RATE PROJECTIONS
- 17.4 DATA TRIANGULATION
- 17.5 RESEARCH ASSUMPTIONS
- 17.6 RESEARCH LIMITATIONS
- 17.7 RISK ANALYSIS
18 APPENDIX
- 18.1 DISCUSSION GUIDE
- 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 18.3 CUSTOMIZATION OPTIONS
- 18.4 RELATED REPORTS
- 18.5 AUTHOR DETAILS
List of Tables
- TABLE 1 IMPACT ANALYSIS: CRO SERVICES MARKET
- TABLE 2 PORTER'S FIVE FORCES ANALYSIS: CRO SERVICES MARKET
- TABLE 3 CRO SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM
- TABLE 4 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025 (USD)
- TABLE 5 INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE, 2025 (USD MILLION)
- TABLE 6 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION)
- TABLE 7 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2026-2027
- TABLE 8 BEST PRACTICES FOLLOWED BY COMPANIES IN CRO SERVICES MARKET
- TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 13 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY
- TABLE 14 BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS
- TABLE 15 CRO SERVICES: ADOPTION BARRIERS & INTERNAL FRICTION
- TABLE 16 CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 17 CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
- TABLE 18 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 19 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 20 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 21 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 22 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 23 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 24 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 25 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 26 CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION, 2024-2031 (USD MILLION)
- TABLE 27 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 28 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 29 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 30 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 31 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY REGION, 2024-2031 (USD MILLION)
- TABLE 32 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE III, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 33 CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024-2031 (USD MILLION)
- TABLE 34 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 35 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 36 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 37 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 38 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY REGION, 2024-2031 (USD MILLION)
- TABLE 39 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE II, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 40 CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024-2031 (USD MILLION)
- TABLE 41 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 42 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 43 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 44 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 45 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY REGION, 2024-2031 (USD MILLION)
- TABLE 46 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE I, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 47 CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024-2031 (USD MILLION)
- TABLE 48 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 49 EUROPE: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 50 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 51 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 52 MIDDLE EAST: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY REGION, 2024-2031 (USD MILLION)
- TABLE 53 GCC COUNTRIES: CLINICAL RESEARCH SERVICES MARKET FOR PHASE IV, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 54 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 55 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 56 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 57 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 58 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 59 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 60 MIDDLE EAST: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 61 GCC COUNTRIES: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 62 CMC SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 63 NORTH AMERICA: CMC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 64 EUROPE: CMC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 65 ASIA PACIFIC: CMC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 66 LATIN AMERICA: CMC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 67 MIDDLE EAST: CMC SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 68 GCC COUNTRIES: CMC SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 69 PRECLINICAL SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 70 PRECLINICAL SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 71 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 72 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 73 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 74 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 75 MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 76 GCC COUNTRIES: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 77 PK/PD SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 78 NORTH AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 79 EUROPE: PK/PD SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 80 ASIA PACIFIC: PK/PD SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 81 LATIN AMERICA: PK/PD SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 82 MIDDLE EAST: PK/PD SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 83 GCC COUNTRIES: PK/PD SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 84 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 85 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 86 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 87 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 88 LATIN AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 89 MIDDLE EAST: TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 90 GCC COUNTRIES: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 91 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 92 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 93 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 94 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 95 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 96 MIDDLE EAST: OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 97 GCC COUNTRIES: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 98 CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 99 NORTH AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 100 EUROPE: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 101 ASIA PACIFIC: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 102 LATIN AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 103 MIDDLE EAST: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 104 GCC COUNTRIES: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 105 LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
- TABLE 106 LABORATORY SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 107 LABORATORY SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 108 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 109 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 110 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 111 LATIN AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 112 MIDDLE EAST: LABORATORY SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 113 GCC COUNTRIES: LABORATORY SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 114 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 115 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 116 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 117 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 118 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 119 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 120 MIDDLE EAST: ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 121 GCC COUNTRIES: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 122 CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION, 2024-2031 (USD MILLION)
- TABLE 123 NORTH AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 124 EUROPE: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 125 ASIA PACIFIC: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 126 LATIN AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 127 MIDDLE EAST: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION, 2024-2031 (USD MILLION)
- TABLE 128 GCC COUNTRIES: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 129 CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 130 NORTH AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 131 EUROPE: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 132 ASIA PACIFIC: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 133 LATIN AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 134 MIDDLE EAST: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 135 GCC COUNTRIES: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 136 CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 137 NORTH AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 138 EUROPE: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 139 ASIA PACIFIC: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 140 LATIN AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 141 MIDDLE EAST: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 142 GCC COUNTRIES: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 143 CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 145 EUROPE: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 147 LATIN AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 148 MIDDLE EAST: CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2024-2031 (USD MILLION)
- TABLE 149 GCC COUNTRIES: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 150 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 151 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 152 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 153 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 154 LATIN AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 155 MIDDLE EAST: OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 156 GCC COUNTRIES: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 157 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 158 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 159 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 160 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 161 LATIN AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 162 MIDDLE EAST: BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 163 GCC COUNTRIES: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 164 CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS
- TABLE 165 CONSULTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 166 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 167 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 168 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 169 LATIN AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 170 MIDDLE EAST: CONSULTING SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 171 GCC COUNTRIES: CONSULTING SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 172 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 173 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 174 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 175 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 176 LATIN AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 177 MIDDLE EAST: DATA MANAGEMENT SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 178 GCC COUNTRIES: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 179 CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 180 CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024-2031 (USD MILLION)
- TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 182 EUROPE: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 184 LATIN AMERICA: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 185 MIDDLE EAST: CRO SERVICES MARKET FOR FSO MODEL, BY REGION, 2024-2031 (USD MILLION)
- TABLE 186 GCC COUNTRIES: CRO SERVICES MARKET FOR FSO MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 187 CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024-2031 (USD MILLION)
- TABLE 188 NORTH AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 189 EUROPE: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 190 ASIA PACIFIC: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 191 LATIN AMERICA: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 192 MIDDLE EAST: CRO SERVICES MARKET FOR FSP MODEL, BY REGION, 2024-2031 (USD MILLION)
- TABLE 193 GCC COUNTRIES: CRO SERVICES MARKET FOR FSP MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 194 CRO SERVICES MARKET FOR HYBRID MODEL, BY REGION, 2024-2031 (USD MILLION)
- TABLE 195 NORTH AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 196 EUROPE: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 197 ASIA PACIFIC: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 198 LATIN AMERICA: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 199 MIDDLE EAST: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 200 GCC COUNTRIES: CRO SERVICES MARKET FOR HYBRID MODEL, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 201 CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 202 CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 203 NORTH AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 204 EUROPE: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 205 ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 206 LATIN AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 207 MIDDLE EAST: CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 208 GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 209 CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 210 NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 211 EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 212 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 213 LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 214 MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 215 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 216 CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 217 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 218 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 219 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 220 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 221 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 222 MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 223 GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 224 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 225 NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 226 EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 227 ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 228 LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 229 MIDDLE EAST: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 230 GCC COUNTRIES: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 231 CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 232 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 233 EUROPE: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 234 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 235 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 236 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 237 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 238 CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 239 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 240 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 241 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 242 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 243 MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 244 GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 245 CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 246 CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 247 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 248 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 249 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 250 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 251 MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 252 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 253 CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 254 NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 255 EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 256 ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 257 LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 258 MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 259 GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 260 CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024-2031 (USD MILLION)
- TABLE 261 NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 262 EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 263 ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 264 LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 265 MIDDLE EAST: CRO SERVICES MARKET FOR INSULIN, BY REGION, 2024-2031 (USD MILLION)
- TABLE 266 GCC COUNTRIES: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 267 CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 268 NORTH AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 269 EUROPE: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 270 ASIA PACIFIC: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 271 LATIN AMERICA: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 272 MIDDLE EAST: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 273 GCC COUNTRIES: CRO SERVICES MARKET FOR COLONY-STIMULATING FACTORS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 274 CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2024-2031 (USD MILLION)
- TABLE 275 NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 276 EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 277 ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 278 LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 279 MIDDLE EAST: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION, 2024-2031 (USD MILLION)
- TABLE 280 GCC COUNTRIES: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 281 CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 282 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 283 EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 284 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 285 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 286 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 287 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 288 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 289 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
- TABLE 290 CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 291 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 292 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 293 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 294 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 295 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 296 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 297 GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 298 CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 299 NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 300 EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 301 ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 302 LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 303 MIDDLE EAST: CRO SERVICES MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 304 GCC COUNTRIES: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 305 CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 306 NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 307 EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 308 ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 309 LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 310 MIDDLE EAST: CRO SERVICES MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 311 GCC COUNTRIES: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 312 CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 313 NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 314 EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 315 ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 316 LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 317 MIDDLE EAST: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 318 GCC COUNTRIES: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 319 CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 320 NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 321 EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 322 ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 323 LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 324 MIDDLE EAST: CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
- TABLE 325 GCC COUNTRIES: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 326 NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2023-2025
- TABLE 327 CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 328 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 329 EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 330 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 331 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 332 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 333 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 334 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 335 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 336 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 337 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 338 LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 339 MIDDLE EAST: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 340 GCC COUNTRIES: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 341 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 342 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 343 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 344 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 345 LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 346 MIDDLE EAST: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 347 GCC COUNTRIES: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 348 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 349 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 350 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 351 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 352 LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 353 MIDDLE EAST: CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 354 GCC COUNTRIES: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 355 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 356 NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 357 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 358 ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 359 LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 360 MIDDLE EAST: CRO SERVICES MARKET FOR VACCINES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 361 GCC COUNTRIES: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 362 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 363 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 364 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 365 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 366 LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 367 MIDDLE EAST: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 368 GCC COUNTRIES: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 369 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 370 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 371 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 372 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 373 LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 374 MIDDLE EAST: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 375 GCC COUNTRIES: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 376 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 377 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 378 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 379 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 380 LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 381 MIDDLE EAST: CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 382 GCC COUNTRIES: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 383 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 384 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 385 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 386 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 387 LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 388 MIDDLE EAST: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 389 GCC COUNTRIES: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 390 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 391 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 392 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 393 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 394 LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 395 MIDDLE EAST: CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 396 GCC COUNTRIES: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 397 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 398 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 399 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 400 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 401 LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 402 MIDDLE EAST: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 403 GCC COUNTRIES: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 404 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 405 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 406 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 407 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 408 LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 409 MIDDLE EAST: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 410 GCC COUNTRIES: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 411 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2024-2031 (USD MILLION)
- TABLE 412 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 413 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 414 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 415 LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 416 MIDDLE EAST: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2024-2031 (USD MILLION)
- TABLE 417 GCC COUNTRIES: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 418 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 419 NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 420 EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 421 ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 422 LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 423 MIDDLE EAST: CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2024-2031 (USD MILLION)
- TABLE 424 GCC COUNTRIES: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 425 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 426 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 427 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 428 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 429 LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 430 MIDDLE EAST: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 431 GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 432 CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 433 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 434 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 435 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 436 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 437 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 438 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 439 MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 440 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 441 CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 442 NORTH AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 443 EUROPE: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 444 ASIA PACIFIC: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 445 LATIN AMERICA: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 446 MIDDLE EAST: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 447 GCC COUNTRIES: CRO SERVICES MARKET FOR LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 448 CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 449 NORTH AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 450 EUROPE: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 451 ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 452 LATIN AMERICA: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 453 MIDDLE EAST: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 454 GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 455 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 456 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 457 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 458 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 459 LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 460 MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 461 GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 462 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 463 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 464 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 465 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 466 LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 467 MIDDLE EAST: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 468 GCC COUNTRIES: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 469 CRO SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 470 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 471 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 472 NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 473 NORTH AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 474 NORTH AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 475 NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 476 NORTH AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 477 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 478 NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 479 NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 480 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 481 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 482 NORTH AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 483 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 484 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 485 US: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 486 US: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 487 US: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 488 US: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 489 US: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 490 US: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 491 US: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 492 US: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 493 US: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 494 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 495 US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 496 US: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 497 US: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 498 US: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 499 CANADA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 500 CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 501 CANADA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 502 CANADA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 503 CANADA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 504 CANADA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 505 CANADA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 506 CANADA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 507 CANADA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 508 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 509 CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 510 CANADA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 511 CANADA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 512 CANADA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 513 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 514 EUROPE: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 515 EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 516 EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 517 EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 518 EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 519 EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 520 EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 521 EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 522 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 523 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 524 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 525 EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 526 EUROPE: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 527 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 528 GERMANY: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 529 GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 530 GERMANY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 531 GERMANY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 532 GERMANY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 533 GERMANY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 534 GERMANY: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 535 GERMANY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 536 GERMANY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 537 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 538 GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 539 GERMANY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 540 GERMANY: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 541 GERMANY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 542 UK: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 543 UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 544 UK: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 545 UK: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 546 UK: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 547 UK: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 548 UK: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 549 UK: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 550 UK: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 551 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 552 UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 553 UK: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 554 UK: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 555 UK: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 556 FRANCE: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 557 FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 558 FRANCE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 559 FRANCE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 560 FRANCE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 561 FRANCE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 562 FRANCE: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 563 FRANCE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 564 FRANCE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 565 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 566 FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 567 FRANCE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 568 FRANCE: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 569 FRANCE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 570 ITALY: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 571 ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 572 ITALY: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 573 ITALY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 574 ITALY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 575 ITALY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 576 ITALY: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 577 ITALY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 578 ITALY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 579 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 580 ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 581 ITALY: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 582 ITALY: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 583 ITALY: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 584 SPAIN: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 585 SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 586 SPAIN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 587 SPAIN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 588 SPAIN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 589 SPAIN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 590 SPAIN: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 591 SPAIN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 592 SPAIN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 593 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 594 SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 595 SPAIN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 596 SPAIN: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 597 SPAIN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 598 REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 599 REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 600 REST OF EUROPE: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 601 REST OF EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 602 REST OF EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 603 REST OF EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 604 REST OF EUROPE: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 605 REST OF EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 606 REST OF EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 607 REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 608 REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 609 REST OF EUROPE: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 610 REST OF EUROPE: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 611 REST OF EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 612 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 613 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 614 ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 615 ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 616 ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 617 ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 618 ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 619 ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 620 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 621 ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 622 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 623 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 624 ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 625 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 626 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 627 CHINA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 628 CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 629 CHINA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 630 CHINA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 631 CHINA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 632 CHINA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 633 CHINA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 634 CHINA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 635 CHINA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 636 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 637 CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 638 CHINA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 639 CHINA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 640 CHINA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 641 INDIA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 642 INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 643 INDIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 644 INDIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 645 INDIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 646 INDIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 647 INDIA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 648 INDIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 649 INDIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 650 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 651 INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 652 INDIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 653 INDIA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 654 INDIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 655 JAPAN: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 656 JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 657 JAPAN: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 658 JAPAN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 659 JAPAN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 660 JAPAN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 661 JAPAN: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 662 JAPAN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 663 JAPAN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 664 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 665 JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 666 JAPAN: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 667 JAPAN: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 668 JAPAN: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 669 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 670 AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 671 AUSTRALIA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 672 AUSTRALIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 673 AUSTRALIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 674 AUSTRALIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 675 AUSTRALIA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 676 AUSTRALIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 677 AUSTRALIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 678 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 679 AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 680 AUSTRALIA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 681 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 682 AUSTRALIA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 683 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 684 SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 685 SOUTH KOREA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 686 SOUTH KOREA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 687 SOUTH KOREA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 688 SOUTH KOREA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 689 SOUTH KOREA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 690 SOUTH KOREA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 691 SOUTH KOREA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 692 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 693 SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 694 SOUTH KOREA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 695 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 696 SOUTH KOREA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 697 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 698 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 699 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 700 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 701 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 702 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 703 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 704 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 705 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 706 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 707 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 708 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 709 REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 710 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 711 LATIN AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 712 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 713 LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 714 LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 715 LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 716 LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 717 LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 718 LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 719 LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 720 LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 721 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 722 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 723 LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 724 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 725 LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 726 BRAZIL: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 727 BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 728 BRAZIL: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 729 BRAZIL: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 730 BRAZIL: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 731 BRAZIL: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 732 BRAZIL: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 733 BRAZIL: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 734 BRAZIL: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 735 BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 736 BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 737 BRAZIL: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 738 BRAZIL: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 739 BRAZIL: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 740 MEXICO: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 741 MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 742 MEXICO: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 743 MEXICO: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 744 MEXICO: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 745 MEXICO: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 746 MEXICO: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 747 MEXICO: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 748 MEXICO: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 749 MEXICO: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 750 MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 751 MEXICO: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 752 MEXICO: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 753 MEXICO: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 754 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 755 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 756 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 757 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 758 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 759 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 760 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 761 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 762 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 763 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 764 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 765 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 766 REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 767 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 768 MIDDLE EAST: CRO SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 769 MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 770 MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 771 MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 772 MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 773 MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 774 MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 775 MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 776 MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 777 MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 778 MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 779 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 780 MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 781 MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 782 MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 783 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 784 GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 785 GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 786 GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 787 GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 788 GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 789 GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 790 GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 791 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 792 GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 793 GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 794 GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 795 GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 796 GCC COUNTRIES: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 797 GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 798 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 799 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 800 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 801 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 802 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 803 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 804 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 805 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 806 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 807 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 808 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 809 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 810 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 811 KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 812 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 813 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 814 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 815 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 816 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 817 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 818 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 819 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 820 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 821 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 822 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 823 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 824 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 825 UNITED ARAB EMIRATES (UAE): CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 826 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 827 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 828 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 829 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 830 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 831 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 832 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 833 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 834 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 835 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 836 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 837 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 838 REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 839 REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 840 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 841 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 842 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 843 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 844 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 845 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 846 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 847 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 848 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 849 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 850 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 851 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 852 REST OF MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 853 REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 854 AFRICA: CRO SERVICES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 855 AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2024-2031 (USD MILLION)
- TABLE 856 AFRICA: CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 857 AFRICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 858 AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 859 AFRICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 860 AFRICA: CRO SERVICES MARKET, BY MODALITY, 2024-2031 (USD MILLION)
- TABLE 861 AFRICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 862 AFRICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 863 AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 864 AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 865 AFRICA: CRO SERVICES MARKET, BY DELIVERY MODEL, 2024-2031 (USD MILLION)
- TABLE 866 AFRICA: CRO SERVICES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 867 AFRICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 868 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026
- TABLE 869 CRO SERVICES MARKET: DEGREE OF COMPETITION
- TABLE 870 CRO SERVICES MARKET: REGION FOOTPRINT
- TABLE 871 CRO SERVICES MARKET: TYPE FOOTPRINT
- TABLE 872 CRO SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
- TABLE 873 CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SME PLAYERS, BY TYPE AND REGION
- TABLE 874 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 875 CRO SERVICES MARKET: DEALS, JANUARY 2023-MARCH 2026
- TABLE 876 CRO SERVICES MARKET: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 877 IQVIA INC.: COMPANY OVERVIEW
- TABLE 878 IQVIA INC.: SERVICES/SOLUTIONS OFFERED
- TABLE 879 IQVIA INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 880 IQVIA INC.: DEALS, JANUARY 2023-MARCH 2026
- TABLE 881 ICON PLC: COMPANY OVERVIEW
- TABLE 882 ICON PLC.: SERVICES/SOLUTIONS OFFERED
- TABLE 883 ICON PLC.: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 884 ICON PLC: DEALS, JANUARY 2023-MARCH 2026
- TABLE 885 ICON PLC.: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 886 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 887 THERMO FISHER SCIENTIFIC INC.: SERVICES/SOLUTIONS OFFERED
- TABLE 888 THERMO FISHER SCIENTIFIC, INC.: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 889 THERMO FISHER SCIENTIFIC, INC.: DEALS, JANUARY 2021-APRIL 2026
- TABLE 890 THERMO FISHER SCIENTIFIC, INC.: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 891 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
- TABLE 892 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES/SOLUTIONS OFFERED
- TABLE 893 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 894 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2023-MARCH 2026
- TABLE 895 LABORATORY CORPORATION OF AMERICA HOLDINGS: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 896 LABORATORY CORPORATION OF AMERICA HOLDINGS: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
- TABLE 897 FORTREA, INC.: BUSINESS OVERVIEW
- TABLE 898 FORTREA, INC.: SERVICES/SOLUTIONS OFFERED
- TABLE 899 FORTREA, INC.: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 900 FORTREA, INC.: DEALS, JANUARY 2023-MARCH 2026
- TABLE 901 FORTREA, INC.: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 902 FORTREA, INC.: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
- TABLE 903 SYNEOS HEALTH: COMPANY OVERVIEW
- TABLE 904 SYNEOS HEALTH: SERVICES/SOLUTIONS OFFERED
- TABLE 905 SYNEOS HEALTH: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 906 SYNEOS HEALTH: DEALS, JANUARY 2023-MARCH 2026
- TABLE 907 WUXI APPTEC: COMPANY OVERVIEW
- TABLE 908 WUXI APPTEC: SERVICES/SOLUTIONS OFFERED
- TABLE 909 WUXI APPTEC: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 910 WUXI APPTEC: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
- TABLE 911 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
- TABLE 912 CHARLES RIVER LABORATORIES: SERVICES/SOLUTIONS OFFERED
- TABLE 913 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2023-MARCH 2026
- TABLE 914 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW
- TABLE 915 PAREXEL INTERNATIONAL CORPORATION: SERVICES/SOLUTIONS OFFERED
- TABLE 916 PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2023-MARCH 2026
- TABLE 917 PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 918 PHARMARON: COMPANY OVERVIEW
- TABLE 919 PHARMARON: SERVICES/SOLUTIONS OFFERED
- TABLE 920 MEDPACE: COMPANY OVERVIEW
- TABLE 921 MEDPACE: SERVICES/SOLUTIONS OFFERED
- TABLE 922 SGS SA: COMPANY OVERVIEW
- TABLE 923 SGS SA: SERVICES/SOLUTIONS OFFERED
- TABLE 924 SGS SA: DEALS, JANUARY 2023-MARCH 2026
- TABLE 925 FRONTAGE LABS: COMPANY OVERVIEW
- TABLE 926 FRONTAGE LABS: SERVICES/SOLUTIONS OFFERED
- TABLE 927 FRONTAGE LABS: DEALS, JANUARY 2023-MARCH 2026
- TABLE 928 FRONTAGE LABS: OTHER DEVELOPMENTS, JANUARY 2023-MARCH 2026
- TABLE 929 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
- TABLE 930 EUROFINS SCIENTIFIC: SERVICES/SOLUTIONS OFFERED
- TABLE 931 TIGERMED: COMPANY OVERVIEW
- TABLE 932 TIGERMED: SERVICES OFFERED
- TABLE 933 TIGERMED: PRODUCT/ SERVICE APPROVALS, JANUARY 2023-MARCH 2026
- TABLE 934 TIGERMED: DEALS, JANUARY 2023-MARCH 2026
- TABLE 935 PSI CRO AG: COMPANY OVERVIEW
- TABLE 936 PSI CRO AG: SERVICES/SOLUTIONS OFFERED
- TABLE 937 PSI CRO AG: SERVICE LAUNCHES, JANUARY 2023-MARCH 2026
- TABLE 938 PSI CRO AG: DEALS, JANUARY 2023-MARCH 2026
- TABLE 939 PSI CRO AG: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 940 BIOAGILE: COMPANY OVERVIEW
- TABLE 941 BIOAGILE: SERVICES/SOLUTIONS OFFERED
- TABLE 942 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
- TABLE 943 FIRMA CLINICAL RESEARCH: SERVICES/SOLUTIONS OFFERED
- TABLE 944 ACCULAB LIFE SCIENCES: COMPANY OVERVIEW
- TABLE 945 ACCULAB LIFE SCIENCES: SERVICES/SOLUTIONS OFFERED
- TABLE 946 NOVOTECH: COMPANY OVERVIEW
- TABLE 947 NOVOTECH: SERVICES/SOLUTIONS OFFERED
- TABLE 948 NOVOTECH HEALTH HOLDINGS: DEALS, JANUARY 2023-MARCH 2026
- TABLE 949 LINICAL: COMPANY OVERVIEW
- TABLE 950 LINICAL: SERVICES/SOLUTIONS OFFERED
- TABLE 951 LINICAL: EXPANSIONS, JANUARY 2023-MARCH 2026
- TABLE 952 ADVANCED CLINICAL: COMPANY OVERVIEW
- TABLE 953 ADVANCED CLINICAL: SERVICES/SOLUTIONS OFFERED
- TABLE 954 ADVANCED CLINICAL: DEALS, JANUARY 2023-MARCH 2026
- TABLE 955 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
- TABLE 956 CRO SERVICES MARKET: RISK ANALYSIS
List of Figures
- FIGURE 1 MARKET SCENARIO
- FIGURE 2 GLOBAL CRO SERVICES MARKET, 2024-2031
- FIGURE 3 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, 2023-2026
- FIGURE 4 DISRUPTIONS INFLUENCING THE GROWTH OF THE CRO SERVICES MARKET
- FIGURE 5 HIGH-GROWTH SEGMENTS IN CRO SERVICES MARKET, 2026-2031
- FIGURE 6 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN THE CRO SERVICES MARKET, IN TERMS OF VALUE, DURING THE FORECAST PERIOD
- FIGURE 7 INCREASING SIZE OF THE CLINICAL DEVELOPMENT PIPELINE TO PROPEL MARKET GROWTH
- FIGURE 8 US AND SMALL MOLECULES SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025
- FIGURE 9 CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
- FIGURE 10 DRIVERS, OPPORTUNITIES, AND CHALLENGES: CRO SERVICES MARKET
- FIGURE 11 ACTIVE PHARMACEUTICAL PIPELINE, 2015-2026
- FIGURE 12 PORTER'S FIVE FORCES ANALYSIS: CRO SERVICES MARKET
- FIGURE 13 CRO SERVICES MARKET: VALUE CHAIN ANALYSIS
- FIGURE 14 CRO SERVICES MARKET: ECOSYSTEM ANALYSIS
- FIGURE 15 INDICATIVE PRICING ANALYSIS (PER STUDY), BY REGION, 2025 (USD MILLION)
- FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESS IN CRO SERVICES MARKET
- FIGURE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES, BY MODALITY
- FIGURE 18 KEY BUYING CRITERIA FOR CRO SERVICES ACROSS END USERS
- FIGURE 19 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2024 VS. 2025
- FIGURE 20 CANCER (%) AS A PROPORTION OF PIPELINE IN DEVELOPMENT, 2013-2024
- FIGURE 21 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
- FIGURE 22 ANNUAL DRUG APPROVALS BY FDA CENTER FOR DRUG EVALUATION AND RESEARCH, 2013-2025
- FIGURE 23 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2013-2024
- FIGURE 24 US FDA DE NOVO MEDICAL DEVICE APPROVALS, 2012-2024
- FIGURE 25 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
- FIGURE 26 GLOBAL DISTRIBUTION OF R&D COMPANIES, JANUARY 2025 VS. JANUARY 2026
- FIGURE 27 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
- FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2021-2025)
- FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET (2025)
- FIGURE 30 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
- FIGURE 31 CRO SERVICES MARKET: COMPANY FOOTPRINT
- FIGURE 32 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
- FIGURE 33 EV/EBITDA OF KEY VENDORS
- FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
- FIGURE 35 CRO SERVICES MARKET: SERVICE COMPARATIVE ANALYSIS
- FIGURE 36 IQVIA INC.: COMPANY SNAPSHOT (2025)
- FIGURE 37 ICON PLC: COMPANY SNAPSHOT (2024)
- FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- FIGURE 39 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2025)
- FIGURE 40 FORTREA, INC.: COMPANY SNAPSHOT
- FIGURE 41 WUXI APPTEC: COMPANY SNAPSHOT
- FIGURE 42 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
- FIGURE 43 PHARMARON: COMPANY SNAPSHOT
- FIGURE 44 MEDPACE: COMPANY SNAPSHOT
- FIGURE 45 SGS SA: COMPANY SNAPSHOT
- FIGURE 46 FRONTAGE LABS: COMPANY SNAPSHOT
- FIGURE 47 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
- FIGURE 48 TIGERMED: COMPANY SNAPSHOT
- FIGURE 49 CRO SERVICES MARKET: RESEARCH DESIGN
- FIGURE 50 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES (DEMAND- AND SUPPLY-SIDE PARTICIPANTS)
- FIGURE 51 GLOBAL CRO SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
- FIGURE 52 GLOBAL CRO SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2025
- FIGURE 53 ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2025
- FIGURE 54 CRO SERVICES MARKET SIZE VALIDATION FROM PRIMARY SOURCES
- FIGURE 55 TOP-DOWN APPROACH
- FIGURE 56 GLOBAL CRO SERVICES MARKET: CAGR PROJECTIONS, 2026-2031
- FIGURE 57 CRO SERVICES MARKET: DATA TRIANGULATION METHODOLOGY
02-2729-4219
+886-2-2729-4219
醫療保健製藥合約開發和生產組織 (CMO) 市場：按服務、分子類型、劑型、應用、治療領域和最終用戶分類——2026-2032 年全球市場預測醫藥合約開發與生產組織 (CDMO) 市場：2026-2032 年全球市場預測（按服務類型、開發階段、最終用途和客戶類型分類）
微型工廠生態系統市場預測至2034年—按工廠類型、部署模式、組件、技術、最終用戶、產業和地區分類的全球分析
2026-2034年全球醫療保健製藥合約開發和生產組織（CDMO）市場規模、佔有率、趨勢和成長分析報告
合約研究組織 (CRO) 服務市場分析及預測（至 2035 年）：按類型、產品類型、服務、技術、應用、最終用戶、流程、實施類型、解決方案和階段分類合約開發和生產組織 (CDMO) 市場分析及預測至 2035 年：類型、產品類型、服務、技術、應用、形式、最終用戶、流程和階段醫藥銷售外包 (CSO) 市場分析及預測（至 2035 年）：按類型、產品、服務、技術、組件、應用領域、最終用戶、流程、部署類型和功能分類
醫藥合約銷售外包市場－全球產業規模、佔有率、趨勢、機會及預測（按服務、治療領域、地區及競爭格局分類，2021-2031年）按包裝類型、溫度範圍、隔熱材料、運輸方式和最終用戶分類的醫藥溫控包裝解決方案市場—2026-2032年全球預測藥品崩壞儀市場按類型、應用和最終用戶分類 - 全球預測 2026-2032
▼